Showing 6951-6960 of 7165 results for "".
- Slight Uptick for Biologics Predicted in EUhttps://practicaldermatology.com/news/20120419-slight_uptick_for_biologics_predicted_in_eu/2459820/In a recent TreatmentTrends© study with EU5 dermatologists, BioTrends Research Group, LLC finds that there has been a slight increase in the use of biologics in all of the EU5 countries except Italy, where usage has remained constant. Future prescribing habits will see moderate increases in prescrib
- Study Shows No Association Between NSAIDs and BCChttps://practicaldermatology.com/news/20120418-study_shows_no_association_between_nsaids_and_bcc/2459821/New data question an association between NSAID use and development of BCC, showing that NSAID use was not associated with subsequent incidence of BCC (HR = 1.04, 95% CI: 0.92–1.16) after adjusting for age, sex and estimated lifetime summer sun exposure among a cohort of 58,213 Caucasian Radiologic T
- Survey Results Address Role of UPF Clothing; Top Sunscreenshttps://practicaldermatology.com/news/20120416-survey_results_address_role_of_upf_clothing_top_sunscreens__results_of_a_survey_conducted_at_the_70th_annual_aad_meeting_reveal_that_an_overwhelming_m/2459823/Results of a survey conducted at the 70th Annual AAD Meeting reveal that an overwhelming majority of dermatologists categorize UPF clothing as a first line of defense in sun protection, followed by sunscreen. Respondents also named their top sunscreen choices. The survey, organized by
- Botox Reaches 10-Year Milestone in Aestheticshttps://practicaldermatology.com/news/20120416-botox_reaches_10-year_milestone_in_aesthetics/2459824/Allergan, Inc. marked the 10-year anniversary of the FDA approval of Botox Cosmetic (onabotulinumtoxinA) to improve the look of moderate to severe frown lines between the eyebrows in patients age 18-65.In the decade since Botox Cos
- Rosacea Awareness: 16 Million Americans Affected, Stressedhttps://practicaldermatology.com/news/20120402-rosacea_awareness_16_million_americans_affected_stressed/2459829/More than 90 percent of more than 1,200 respondents with rosacea said they suffered some form of physical pain from rosacea, according to a new survey by the National Rosacea Society (NRS). With April designated as Rosacea Awareness Month, the NRS strives to educate the public on the effects of rosa
- Medical Students Not Concerned About Skin Cancershttps://practicaldermatology.com/news/20120326-medical_students_not_concerned_about_skin_cancers/2459831/Medical students understand the causes of skin cancer but may be confused about SPF and sunscreen use, comments in recent focus groups suggest. (Arch Dermatol. 148(3):392-393) Surprisingly, most medical students
- Ulthera Cleared in Mexicohttps://practicaldermatology.com/news/20120320-ulthera_cleared_in_mexico/2459837/Ulthera is now registered in Mexico to market and distribute its ultrasound therapy device, the Ulthera System. In Mexico, the system is now prescribed to produce stimulation in tissues to raise the temperature in a localized manner for aesthetic
- EHR iPad App Now Features Speech Recognitionhttps://practicaldermatology.com/news/20120320-ehr_ipad_app_now_features_speech_recognition/2459838/The EZ DERM EHR iPad app is now powered by the cloud-based Nuance Healthcare 360 | Development Platform. The speech recognition platform provides CPU intensive speech and
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Commercialization of MelaFind Now Underwayhttps://practicaldermatology.com/news/20120314-commercialization_of_melafind_now_underway/2459843/MELA Sciences, Inc. (NASDAQ: MELA) this week announced that the company has begun commercialization of MelaFind, as part of a controlled and deliberate launch in the U.S. and in Germany. "We are enthusiastic about the success of our final b